Combining targeted therapies known as tyrosine kinase inhibitors (TKIs) can be an effective way to treat a mutation-driven form of lung cancer in cases where tumors develop resistance to treatment and where cancer has spread to other parts of the body, a University of Colorado Cancer Center member reports.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045